Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
niraparib (67) 67
oncology (34) 34
ovarian cancer (34) 34
index medicus (31) 31
olaparib (25) 25
rucaparib (20) 20
parp inhibitors (19) 19
poly polymerase (17) 17
cancer (16) 16
chemotherapy (16) 16
parp inhibitor (16) 16
pharmacology & pharmacy (15) 15
homologous recombination (11) 11
humans (11) 11
maintenance therapy (10) 10
platinum (10) 10
breast cancer (9) 9
inhibitors (9) 9
medicine & public health (9) 9
monosaccharides (8) 8
open-label (8) 8
sugars (8) 8
bevacizumab (7) 7
dna repair (7) 7
double-blind (7) 7
female (7) 7
mutation (7) 7
olaparib maintenance therapy (7) 7
pharmacokinetics (7) 7
review (7) 7
ribose (7) 7
tumors (7) 7
veliparib (7) 7
analysis (6) 6
carcinoma (6) 6
mk-4827 (6) 6
obstetrics & gynecology (6) 6
ovarian neoplasms - drug therapy (6) 6
patients (6) 6
polymerase (6) 6
talazoparib (6) 6
therapy (6) 6
adp (5) 5
antitumor-activity (5) 5
brca (5) 5
breast-cancer (5) 5
cancer therapies (5) 5
endocrine system diseases (5) 5
inhibitor (5) 5
mutations (5) 5
neoplasms. tumors. oncology. including cancer and carcinogens (5) 5
parp (5) 5
pharmacology/toxicology (5) 5
repair (5) 5
toxicity (5) 5
cancer research (4) 4
cell line, tumor (4) 4
dna damage (4) 4
epithelial ovarian cancer (4) 4
fallopian-tube (4) 4
grade serous ovarian (4) 4
homologous recombination deficiency (4) 4
inhibitor niraparib (4) 4
negative breast-cancer (4) 4
ovarian carcinoma (4) 4
poly (4) 4
poly polymerase inhibitors (4) 4
primary peritoneal (4) 4
recurrent (4) 4
resistance (4) 4
survival (4) 4
thrombocytopenia (4) 4
53bp1 (3) 3
ams (3) 3
anemia (3) 3
article (3) 3
bioavailability (3) 3
biotechnology (3) 3
brca mutation carriers (3) 3
brca mutations (3) 3
cells (3) 3
clinical trials (3) 3
combination (3) 3
confidence intervals (3) 3
deoxyribonucleic acid--dna (3) 3
drug approval (3) 3
durvalumab (3) 3
fallopian tube (3) 3
female genital diseases and pregnancy complications (3) 3
liquid chromatography (3) 3
mass spectrometry (3) 3
medical colleges (3) 3
medical research (3) 3
metabolites (3) 3
multicenter (3) 3
ovarian neoplasms - genetics (3) 3
pegylated liposomal doxorubicin (3) 3
peritoneum (3) 3
pharmacology (3) 3
platinum-sensitive ovarian (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Maintenance poly (ADP-ribose) polymerase inhibitor therapy for ovarian cancer: Precision oncology or one size fits all?
by Berchuck, Andrew and Secord, Angeles Alvarez and Moss, Haley A and Havrilesky, Laura J
Journal of Clinical Oncology, ISSN 0732-183X, 12/2017, Volume 35, Issue 36, pp. 3999 - 4002
MULTICENTER | ONCOLOGY | RECURRENT | OPEN-LABEL | CHEMOTHERAPY | PHASE-2 TRIAL | NIRAPARIB
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Determination of the absolute oral bioavailability of niraparib by simultaneous administration of aC-microtracer and therapeutic dose in cancer patients
by van Andel, L and Rosing, H and Zhang, Z and Hughes, L and Kansra, V and Sanghvi, M and Tibben, M and Gebretensae, A and Schellens, J H M and Beijnen, J H
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 01/2018, Volume 81, Issue 1, p. 39
INTRODUCTION: Niraparib (Zejula™) is a poly(ADP-ribose) polymerase inhibitor recently approved by the US Food and Drug Administration for the maintenance... 
LC-MS/MS | 14C-microtracer | AMS | Niraparib | Bioavailability | Pharmacokinetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Niraparib for the treatment of ovarian cancer
by Essel, Kathleen G and Moore, Kathleen N
Expert Review of Anticancer Therapy, ISSN 1473-7140, 08/2018, Volume 18, Issue 8, pp. 727 - 733
Introduction: Niraparib, an orally available selective inhibitor of poly(adenosine diphosphate-ribose) polymerase (PARP), is the first PARP inhibitor approved... 
BRCA | Niraparib | ovarian cancer | homologous recombination deficiency | PARP inhibitor | GERMLINE | MANAGEMENT | SAFETY | INHIBITOR NIRAPARIB | ANTITUMOR-ACTIVITY | MAINTENANCE THERAPY | ONCOLOGY | RECURRENT | BRCA1/2 MUTATION | PARP INHIBITORS | CARCINOMA | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Identifying the need to refine the potential patient risk factors for niraparib-induced thrombocytopenia
by Smith, Judith A and Le, Tran and Martin, Grace A and Gaikwad, Anjali and Sun, Chenchen H and Nugent, Elizabeth K and Lucci, Joseph A
Gynecologic Oncology, ISSN 0090-8258, 02/2019, Volume 152, Issue 2, pp. 265 - 269
Niraparib is a poly (ADP-ribose) polymerase inhibitor (PARP) approved for use in maintenance therapy for ovarian cancer that is associated with the... 
Thrombocytopenia | Niraparib | Creatinine clearance | Drug interactions | PARP inhibitors | ONCOLOGY | INHIBITOR | OBSTETRICS & GYNECOLOGY | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Determination of the DNA binding properties of a novel PARP inhibitor MK-4827 with calf-thymus DNA by molecular simulations and detailed spectroscopic investigations
by Yang, HQ and Zeng, QL and He, Z and Wu, D and Li, H
NEW JOURNAL OF CHEMISTRY, ISSN 1144-0546, 05/2019, Volume 43, Issue 17, pp. 6702 - 6711
The binding interaction of niraparib (MK-4827), a poly(ADP-ribose) polymerase inhibitor, with calf thymus deoxyribonucleic acid (ctDNA) has been explored by... 
CTDNA | THERAPY | PARAMETERIZATION | HUMAN SERUM-ALBUMIN | DOCKING | SITES | MECHANISMS | DERIVATIVES | CHEMISTRY, MULTIDISCIPLINARY | NIRAPARIB
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24
by Mirza, Mansoor Raza and Bergmann, Troels K and Mau-Sørensen, Morten and Christensen, René dePont and Åvall-Lundqvist, Elisabeth and Birrer, Michael J and Jørgensen, Morten and Roed, Henrik and Malander, Susanne and Nielsen, Flemming and Lassen, Ulrik and Brøsen, Kim and Bjørge, Line and Mäenpää, Johanna and Medicinska fakulteten and Region Östergötland and Linköpings universitet and Institutionen för klinisk och experimentell medicin and Onkologiska kliniken US and Centrum för kirurgi, ortopedi och cancervård and Avdelningen för Kirurgi, Ortopedi och Onkologi
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 10/2019, Volume 84, Issue 4, pp. 791 - 798
Combining poly(ADP-ribose) polymerase (PARP) inhibitors with antiangiogenic agents appeared to enhance activity vs PARP inhibitors alone in a randomized phase... 
BRCA | Medicine & Public Health | PARP inhibitor | Oncology | Cancer Research | Niraparib | Pharmacology/Toxicology | Ovarian cancer | Bevacizumab | Ovarian carcinoma | Toxicity | Poly(ADP-ribose) | ADP | Confidence intervals | Ribose | Platinum | Quality | Safety engineering | Antiangiogenic agents | Hypertension | BRCA2 protein | Thrombocytopenia | Anemia | Poly(ADP-ribose) polymerase | Breast cancer | Constraining | Polymerase | Inhibitors | Antiangiogenics | Mutation | Pharmacokinetics | Cancer | Index Medicus | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Cancer and Oncology | Klinisk medicin | Cancer och onkologi | Niraparib; PARP inhibitor; Ovarian cancer; Bevacizumab; BRCA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models
by Sun, Kaiming and Mikule, Keith and Wang, Zebin and Poon, Grace and Vaidyanathan, Aparajitha and Smith, Gillian and Zhang, Zhi-Yi and Hanke, Jeffrey and Ramaswamy, Sridhar and Wang, Jing
Oncotarget, ISSN 1949-2553, 12/2018, Volume 9, Issue 98, pp. 37080 - 37096
Niraparib is an orally bioavailable and selective poly (ADP-ribose) polymerase (PARP)-1/-2 inhibitor approved for maintenance treatment of both mutant (mut)... 
Niraparib | Brain exposure | Tumor exposure | BRCAwt tumor | Intracranial tumor
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer
by Liu, Chia-Hao and Chang, Yi and Wang, Peng-Hui
Taiwanese Journal of Obstetrics & Gynecology, ISSN 1028-4559, 10/2017, Volume 56, Issue 5, pp. 713 - 714
THERAPY | NIRAPARIB | OBSTETRICS & GYNECOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Human mass balance study and metabolite profiling of C-14-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer
by van Andel, L and Zhang, Z and Lu, S and Kansra, V and Agarwal, S and Hughes, L and Tibben, MM and Gebretensae, A and Lucas, L and Hillebrand, MJX and Rosing, H and Schellens, JHM and Beijnen, JH
INVESTIGATIONAL NEW DRUGS, ISSN 0167-6997, 12/2017, Volume 35, Issue 6, pp. 751 - 765
Niraparib is an investigational oral, once daily, selective poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor. In the pivotal Phase 3 NOVA/ENGOT/OV16... 
Mass balance | TRA | Radiolabelled | Metabolites | ONCOLOGY | ADME | Niraparib | PHARMACOLOGY & PHARMACY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Latest clinical evidence and further development of PARP inhibitors in ovarian cancer
by Mirza, M R and Pignata, S and Ledermann, J A
Annals of Oncology, ISSN 0923-7534, 06/2018, Volume 29, Issue 6, pp. 1366 - 1376
Abstract For several decades, the systemic treatment of ovarian cancer has involved chemotherapy, with the relatively recent addition of antiangiogenic... 
Phase III | Niraparib | Olaparib | Rucaparib | PARP inhibitor | Ovarian cancer | GRADE SEROUS OVARIAN | ovarian cancer | phase III | FALLOPIAN-TUBE | ANTITUMOR-ACTIVITY | OLAPARIB MAINTENANCE THERAPY | BREAST-CANCER | DOSE-ESCALATION | PARR inhibitor | rucaparib | ONCOLOGY | olaparib | niraparib | DOUBLE-BLIND | EPITHELIAL OVARIAN | PRIMARY PERITONEAL | BRCA2 MUTATION
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Niraparib for the treatment of ovarian cancer
by Kanjanapan, Yada and Lheureux, Stephanie and Oza, Amit M
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 04/2017, Volume 18, Issue 6, pp. 631 - 640
Introduction: Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors are being developed in maintenance and recurrence treatment settings in ovarian... 
Niraparib | BRCA1/2 mutation | ovarian cancer | homologous recombination deficiency | maintenance | OPEN-LABEL | SECONDARY CYTOREDUCTIVE SURGERY | INHIBITOR NIRAPARIB | COMBINATION | MAINTENANCE THERAPY | CHEMOTHERAPY | BREAST | OLAPARIB | PHARMACOLOGY & PHARMACY | RECURRENT EPITHELIAL OVARIAN | RECOMBINATION DEFICIENCY HRD | BRCA1 Protein - genetics | Disease-Free Survival | Piperidines - therapeutic use | Humans | Female | Mutation | Ovarian Neoplasms - drug therapy | BRCA2 Protein - genetics | Indazoles - therapeutic use | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Randomized Controlled Trials as Topic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer
by Hurley, Rachel M and Henickson, Anea E. Wahner and Visscher, Daniel W and Ansel, Peter and Harrell, Maria I and Wagner, Jill M and Negron, Vivian and Goergen, Krista M and Maurer, Matthew J and Oberg, Ann L and Meng, X. Wei and Flatten, Karen S and De Jonge, Maja J. A and Van Herpen, Carla D and Gietema, Jourik A and Koornstra, Rutger H. T and Jager, Agnes and den Hollander, Martha W and Dudley, Matthew and Shepherd, Stacie P and Swisher, Elizabeth M and Kaufmann, Scott H
Gynecologic Oncology, ISSN 0090-8258, 04/2019, Volume 153, Issue 1, pp. 127 - 134
Objective. Poly(ADP-ribose) polymerase (PARP) inhibitors have shown substantial activity in homologous recombination- (HR-) deficient ovarian cancer and are... 
CELLS | PROFICIENT | MULTICENTER | 53BP1 | PARP inhibitors | DNA damage | OPEN-LABEL | Ovarian cancer | NIRAPARIB | REPAIR | POLYMERASE INHIBITORS | RESISTANCE | MUTATIONS | HR-deficiency | CARCINOMA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text PARP inhibitors in ovarian cancer
by Franzese, Elisena and Centonze, Sara and Diana, Anna and Carlino, Francesca and Guerrera, Luigi Pio and Di Napoli, Marilena and De Vita, Ferdinando and Pignata, Sandro and Ciardiello, Fortunato and Orditura, Michele
Cancer Treatment Reviews, ISSN 0305-7372, 02/2019, Volume 73, pp. 1 - 9
Poly-ADP-ribose polymerase inhibitors (PARPis) are the most active and interesting therapies approved for the treatment of epithelial ovarian cancer. They have... 
Niraparib | Olaparib | Rucaparib | PARP inhibitors | Ovarian cancer | BRCA2 MUTATIONS | MUTATION CARRIERS | OPEN-LABEL | MAINTENANCE THERAPY | NEGATIVE BREAST-CANCER | ONCOLOGY | DOUBLE-BLIND | HOMOLOGOUS RECOMBINATION | PHASE-I | CARCINOMA | Medical colleges | Drug approval | Sugars | Monosaccharides
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. The novel PARP inhibitor in recurrent ovarian cancer: niraparib
by He, Gai-Yi-Nan and Jian, Xiao-Shun and Yin, Yi-Zi
Chinese Journal of New Drugs, ISSN 1003-3734, 08/2018, Volume 27, Issue 15, pp. 1714 - 1717
Poly(ADP-ribose) polymerase | Niraparib | Inhibitor | Ovarian cancer
Journal Article
Details down arrow
15. Niraparib: A new PARP-inhibitor for maintenance treatment of platinum-sensitive relapsed ovarian cancer
by Nguyen, My-Hanh
Arzneimitteltherapie, ISSN 0723-6913, 10/2018, Volume 36, Issue 10, pp. 340 - 345
Platinum-sensitive relapsed ovarian cancer | Niraparib | PARP 1/2 inhibitor
Journal Article
Details down arrow
16. Full Text Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo-propyl)pyrrolidine-3-yl)-1H-benzo[d]imidazole-4-carboxamide: A Potent Poly(ADP-ribose) Polymerase (PARP) Inhibitor for Treatment of Cancer
by Min, Rui and Wu, Weibin and Wang, Mingzhong and Tang, Lin and Chen, Dawei and Zhao, Huan and Zhang, Cunlong and Jiang, Yuyang
Molecules, ISSN 1420-3049, 05/2019, Volume 24, Issue 10, p. 1901
A series of benzimidazole carboxamide derivatives have been synthesized and characterized by H-1-NMR, C-13-NMR and HRMS. PARP inhibition assays and cellular... 
Poly(ADP-ribose) polymerase | Benzimidazole carboxamide | PARP enzyme inhibition | benzimidazole carboxamide | DESIGN | poly(ADP-ribose) polymerase | BIOCHEMISTRY & MOLECULAR BIOLOGY | CHEMISTRY, MULTIDISCIPLINARY | NIRAPARIB
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells
by Booth, Laurence and Roberts, Jane L and Samuel, Peter and Avogadri-Connors, Francesca and Cutler, Richard E and Lalani, Alshad S and Poklepovic, Andrew and Dent, Paul
Cancer Biology & Therapy, ISSN 1538-4047, 06/2018, Volume 19, Issue 6, pp. 525 - 533
The irreversible ERBB1/2/4 inhibitor neratinib has been shown to rapidly down-regulate the expression of ERBB1/2/4 as well as the levels of c-MET, PDGFRα and... 
neratinib | receptor tyrosine kinase | Autophagy | niraparib | POLY(ADP-RIBOSE) POLYMERASE | TUMORS | BREAST-CANCER | BECLIN 1 EXPRESSION | ONCOLOGY | IN-VIVO | LINE | RESISTANCE | RECEPTORS | CARCINOMA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Research progress in niraparib in the treatment of ovarian cancer
by Zhang, Shan and Feng, Guosheng
Tumor, ISSN 1000-7431, 05/2018, Volume 38, Issue 5, pp. 508 - 512
Ovarian neoplasms | Poly (ADP-ribose) polymerase inhibitors | Niraparib | Antineoplastic protocols
Journal Article
Details down arrow
19. Full Text Advances in the use of PARP inhibitor therapy for breast cancer
by McCann, Kelly E and Hurvitz, Sara A
Drugs in Context, ISSN 1745-1981, 08/2018, Volume 7, pp. 212540 - 30
Poly-ADP-ribose polymerase 1 (PARP-1) and PARP-2 are DNA damage sensors that are most active during S-phase of the cell cycle and that have wider-reaching... 
Rucaparib | PARP inhibitor | Veliparib | Niraparib | Breast cancer | Olaparib | Talazoparib | BRCA1 | BRCA2 | rucaparib | niraparib | olaparib | breast cancer | veliparib | talazoparib
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Determination of interactions between human serum albumin and niraparib through multi-spectroscopic and computational methods
by Gan, Na and Sun, Qiaomei and Tang, Peixiao and Wu, Di and Xie, Tonghui and Zhang, Yongkui and Li, Hui
Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, ISSN 1386-1425, 01/2019, Volume 206, pp. 126 - 134
The interactions between 2-{4-[(3 )-piperidin-3-yl] phenyl}-2H-indazole-7-carboxamide (niraparib) and human serum albumin (HSA) were investigated through... 
Fluorescence | Human serum albumin | Niraparib | Molecular dynamics simulation | Molecular docking | DRUG | ACID | X-RAY CRYSTALLOGRAPHY | MECHANISM | CONFORMATION | MASS-SPECTROMETRY | NANOPARTICLES | SPECTROSCOPY | BINDING | Molecular dynamics | Albumin | Thermodynamics | Analysis | Methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.